Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8161 to 8175 of 8905 results

  1. Cenegermin for treating neurotrophic keratitis (TA532)

    We have withdrawn the guidance because cenegermin (Oxervate) is no longer available in the UK.

    Withdrawn guidance

  2. Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)

    This guidance has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  3. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA802.

    Withdrawn guidance

  4. Fremanezumab for preventing migraine (TA631)

    This guidance has been updated and replaced by NICE technology appraisal guidance 764.

    Withdrawn guidance

  5. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1118. People already having entrectinib for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours through the Cancer Drugs Fund will be able to continue until they and their healthcare professional decide when best to stop.

    Withdrawn guidance

  6. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1120.

    Withdrawn guidance

  7. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654 

    Withdrawn guidance

  8. Sotagliflozin with insulin for treating type 1 diabetes (TA622)

    NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.  

    Withdrawn guidance

  9. Glitazones in the treatment of type 2 diabetes (TA63)

    This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).

    Withdrawn guidance

  10. Guidance on the use of photodynamic therapy for age-related macular degeneration (TA68)

    This guidance has been updated and replaced by NICE guideline NG82.

    Withdrawn guidance

  11. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.

    Withdrawn guidance

  12. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.

    Withdrawn guidance

  13. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

    This guidance has been updated and replaced by NICE technology appraisal guidance 687.

    Withdrawn guidance

  14. Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1059.

    Withdrawn guidance

  15. Dapagliflozin with insulin for treating type 1 diabetes (TA597)

    In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.

    Withdrawn guidance